Rubius (RUBY) PT Raised to $40 at H.C. Wainwright, Following Clinical Update
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
H.C. Wainwright analyst Andrew S. Fein raised the price target on Rubius (NASDAQ: RUBY) to $40.00 (from $28.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubius Therapeutics (RUBY) Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors
- Schroders Plc (SDR:LN) (SHNWF) PT Raised to GBP29.20 at Goldman Sachs
- SCREEN Holdings Co Ltd. (7735:JP) (DINRF) PT Raised to JPY12,300 at Macquarie
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesH.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!